Mebendazole and insulin secretion from isolated rat islets

Area of Science:

• Endocrinology
• Pharmacology
• Metabolic Research

Background:

• Preliminary studies suggested mebendazole, an anti-parasitic agent, may improve glycemic control in type II diabetes patients.
• Observed effects included decreased plasma glucose and free fatty acids, and increased C-peptide, hinting at insulin secretagogue properties.
• Previous findings were from uncontrolled studies, necessitating investigation into direct drug effects on insulin secretion.

Purpose of the Study:

• To investigate the direct effect of mebendazole on insulin secretion from pancreatic islets.
• To determine if mebendazole acts as an insulin secretagogue independent of systemic metabolic influences.

Main Methods:

• Intact pancreatic islets were isolated from normal rat pancreata.
• Isolated islets were perifused with mebendazole at varying concentrations (10-20 mumol/L).
• Acute-phase insulin release was measured in response to mebendazole, with and without glucose stimulation.

Main Results:

• Mebendazole significantly increased acute-phase insulin release from isolated rat islets.
• A twofold to threefold increase in insulin release was observed at concentrations of 10-20 mumol/L.
• This heightened insulin secretion occurred even in the presence of glucose-stimulated insulin release.

Conclusions:

• Mebendazole directly stimulates insulin secretion from pancreatic islet cells.
• The findings support the hypothesis that mebendazole is an insulin secretagogue.
• Mebendazole represents a potential therapeutic agent for enhancing insulin secretion in diabetes management.